HERTFORDSHIRE, England, PITTSBURGH and SYDNEY, July 8, 2019 – Global pharmaceutical company Mylan N.V.(NASDAQ: MYL) and medical device manufacturer Atomo Diagnostics today announced that the Mylan HIV Self Test, a handheld in vitro HIV rapid diagnostic test for self-testing, has received Prequalification approval by the World Health Organization (WHO...
Today, Atomo Diagnostics and partner Mylan have jointly announced that the Mylan HIV Self Test, a handheld in vitro HIV rapid diagnostic test for self-testing, has received Prequalification approval by the World Health Organization (WHO PQ). The WHO PQ process includes a rigorous evaluation of the test’s...
Seoul, Korea and Sydney, Australia – 29 April 2019 | Access Bio Inc. and Atomo Diagnostics today announced that they have developed a best-in-class rapid diagnostic test (RDT) for screening for hepatitis C virus (HCV). The companies have also collaborated to create a version for professional...
HERTFORDSHIRE, England, PITTSBURGH and SYDNEY, September 24, 2018 – Global pharmaceutical company Mylan N.V.(NASDAQ: MYL) and medical device company Atomo Diagnostics today announced a strategic partnership to commercialize CE-Marked in vitro HIV rapid diagnostic tests for self-testing in low- and middle-income countries. The tests will allow...
Today, Atomo Diagnostics and Owen Mumford Ltd announced a strategic partnership for commercialisation of innovative HIV rapid tests in European markets Owen Mumford is a major healthcare company and device manufacturer that commercialises pioneering medical products in its own brand to enhance access to diagnostics, encourage...
Sydney, Australia and Woodstock, England – 05 June 2018 | Atomo Diagnostics and Owen Mumford Ltd have today announced a strategic partnership for commercialisation of innovative HIV rapid tests in European markets Owen Mumford acquires exclusive rights to Atomo’s HIV rapid tests for commercialisation under...
RPS Diagnostics partners with Atomo Diagnostics to develop next generation FebriDx blood tests for antibiotic stewardship in the outpatient setting Sarasota, Florida and Sydney, Australia (February 20, 2018) – United States biotechnology company, RPS Diagnostics (RPS®), and Australian medical device company, Atomo Diagnostics, announced today that...
Today, Atomo Diagnostics and Access Bio Inc. jointly announced a strategic partnership to leverage the respective strengths of both companies and expand point of care HIV testing in global markets. Atomo will supply its award-winning AtomoRapid™ lateral flow diagnostic test platforms for use with Access Bio’s in vitro HIV rapid...
Atomo Diagnostics' CEO, John Kelly, today announced that the Atomo HIV Self Test has been approved by the World Health Organisation’s Expert Review Panel for Diagnostics (ERP-D); a special process determined by Unitaid and The Global Fund to expedite access to innovative diagnostic products in advance...
Sydney, Australia, 7 December 2017 | Atomo Diagnostics, the world leader in integrated point-of-care rapid diagnostic devices, announced today that its Atomo HIV Self Test has been confirmed as eligible for procurement by organisations entitled to access Global Fund and Unitaid resources. Atomo HIV Self...
Written by CEO, John Kelly: As I read the news, on this World AIDS Day, I am heartened to see so many positive and inspiring stories about the progress being made in communities around the world in the ongoing fight against HIV/AIDS. Nonetheless, it is clear...